[3] In 2006, Vectura acquired Innovata Biomed plc, another developer of pulmonary products,[5] and then moved onto the full list of the London Stock Exchange.

After Vectura decided to concentrate on inhaled products, in June 2021 the company supported a buy-out of the site by its management, with finance from Bpifrance.

[8] In July 2021, American tobacco company Philip Morris International made an offer to buy Vectura Group for £1 billion.

[12] In December 2024, three months after an agreement between the parties was announced, Vectura was acquired by the American manufacturing company Molex (a subsidiary of Koch, Inc.).

[16] The British Thoracic Society made the following statement: Vectura, a company that for over 20 years has worked to treat lung disease, is now part of the tobacco industry.

[3] The headquarters and development facility at Chippenham, England, on a mixed industrial site on the outskirts of the town, employed around 250 as of 2022[update].